

## External Quality Assessment Program for SARS-CoV-2

Labquality is organizing an EQA round for SARS-CoV-2 (COVID-19) detection. The new EQA combo scheme includes individual samples for both molecular diagnostics as well as for serological testing. The participants can choose to order both products or just one product type according to their needs.

### EQA Scheme information

The SARS-CoV-2 EQA scheme is targeted to medical laboratories and POCT sites. Evaluation of the results is qualitative (pos/neg). There are two rounds available in 2020. The first round in May will be a pilot survey free of charge for a limited number of participants. The second round will be sent out in September.

### Products

- **5676 SARS-CoV-2, nucleic acid detection**

2 - 3 SARS-CoV-2 pos/neg samples will be included either as liquid samples or as swab samples. Each sample should be extracted by the recommended nucleic acid extraction method for the assay used by the participant.

Samples contain a whole-genome product that includes all genetic sequences of the virus and emulate real patient samples. As such, the product used contains all possible NAT viral targets ensuring compatibility across all nucleic acid tests. The samples are non-infectious and stable.

- **5677 SARS-CoV-2, antibody detection**

2 - 3 Anti-SARS-CoV-2 IgG/IgM pos/neg samples will be included (approx. 0.5 mL/sample). Samples will be one-donor/pooled samples of human sera or plasma.

### Registration

Please register to the pilot survey by May 4, 2020 via Labquality's local partner or contact our customer service [info@labquality.fi](mailto:info@labquality.fi).

### More information

Heidi Berghäll, Development Manager

[heidi.berghall@labquality.fi](mailto:heidi.berghall@labquality.fi)

+358 50 356 0503

Marsa Järvenpää, EQA coordinator

[marsa.jarvenpaa@labquality.fi](mailto:marsa.jarvenpaa@labquality.fi)

+358 9 8566 8200